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The heparin-binding growth factor midkine (MK) is the product of a retinoic acid-responsive gene, and is implicated in neuronal
survival and differentiation, and carcinogenesis. We previously reported that MK mRNA expression is elevated in neuroblastoma
specimens at all stages, whereas pleiotrophin, the other member of the MK family, is expressed at high levels in favourable
neuroblastomas. As MK is a secretory protein, it can be detected in the blood. Here, we show a significant correlation of the plasma
MK level with prognostic factors of neuroblastomas. The plasma MK level was determined in 220 patients with neuroblastomas, and
compared with that in children without malignant tumors (n¼17, o500pgml
 1). The plasma MK level became significantly elevated
with advancing stages (stage 1: 445pgml
 1 (median), n¼73; stage 2: 589, n¼39; stage 3: 864, n¼40; stage 4: 1445, n¼56; and
stage 4S: 2439, n¼12). More importantly, a higher MK level was strongly correlated with poor prognostic factors: over 1 year of age
(P¼0.0299), MYCN amplification (Po0.0001), low TrkA expression (P¼0.0005), nonmass screening, sporadic neuroblastomas
(Po0.0001), and diploidy/tetraploidy (P¼0.0007). Thus, these results demonstrate that the plasma MK level is a good marker for
evaluating the progression of neuroblastomas. Moreover, considering the ability of antisense MK oligodeoxyribonucleotide to
suppress tumour growth of colorectal carcinoma cells in nude mice, as recently reported, the present study suggests that MK is a
possible candidate molecular target for therapy for neuroblastomas.
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Midkine (MK) is a heparin-binding growth factor that was
originally discovered as the product of a retinoic acid-responsive
gene during the differentiation of embryonal carcinoma cells
(Kadomatsu et al, 1988; Tomomura et al, 1990; Muramatsu, 2002).
The MK family consists of only two members, namely MK and
pleiotrophin (PTN; also called HB-GAM), and is distinct from
other heparin-binding growth factor families (Kurtz et al, 1995;
Rauvala et al, 2000; Deuel et al, 2002; Muramatsu, 2002). Regarding
the biological roles of MK, at least three important issues should be
pointed out. First, a pivotal role of MK in the migration of
inflammatory cells has been revealed by studies involving MK
knockout mice; MK-deficient mice are more resistant to vascular
restenosis and nephritis induced by reperfusion (Horiba et al,
2000; Sato et al, 2001). Second, MK exhibits neuroprotective
activity (Michikawa et al, 1993; Unoki et al, 1994; Owada et al,
1999), and enhances neurite extension (Muramatsu et al, 1993).
Induction of MK expression has been detected in reactive
astrocytes in ischaemic lesions in human and animal brains
(Wang et al, 1998; Wada et al, 2002). MK is deposited at senile
plaques and neurofibrillary tangles in Alzheimer’s patients
(Yasuhara et al, 1993). MK binds to Ab and inhibits its cytotoxicity
(Yu et al, 1998). Third, MK is involved in carcinogenesis. Its
expression is induced as early as at the precancerous stages of
human colorectal and prostate carcinomas (Konishi et al, 1999; Ye
et al, 1999), increases with the stages of human carcinomas, and is
significantly linked to the prognosis (O’Brien et al, 1996; Mishima
et al, 1997). MK transforms NIH3T3 cells (Kadomatsu et al, 1997),
enhances fibrinolysis (Kojima et al, 1995), and promotes cell
growth (Muramatsu and Muramatsu, 1991; Muramatsu et al, 1993;
Takei et al, 2001), cell survival (Qi et al, 2000), cell migration
(Takada et al, 1997; Maeda et al, 1999; Horiba et al, 2000; Qi et al,
2001), and angiogenesis (Choudhuri et al, 1997). MK antisense
oligodeoxyribonucleotide suppresses tumour progression in nude
mice (Takei et al, 2001, 2002).
The neuroblastoma is the most common solid malignant tumour
in children. However, the molecular mechanisms underlying its
pathogenesis and progression remain unclear, although several
molecules, such as MYCN, TrkA, and TrkB, that are linked to the
prognosis have been revealed (Brodeur et al, 1984; Nakagawara
et al, 1995). This is one of the reasons why satisfactorily efficient
therapies have not been established yet. A possible approach
regarding such therapies is to seek molecular targets in
neuroblastomas. We previously reported that MK mRNA expres-
sion is elevated in neuroblastoma specimens at all stages
(Nakagawara et al, 1995). Interestingly, the other MK family
member, PTN, is expressed at high levels in favourable
neuroblastomas (Nakagawara et al, 1995). As MK is a secretory Received 27 November 2002; accepted 25 February 2003
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yprotein, the blood MK level could be a strong tool for monitoring
the status of neuroblastomas. This paper demonstrates that an
elevated plasma level of MK is indeed significantly correlated with
poor prognostic factors. Our results also indicate that MK could be
a candidate molecular target for therapy for neuroblastomas.
MATERIALS AND METHODS
Enzyme-linked immunoassay for human MK
An enzyme-linked immunoassay (EIA) for human MK was
performed as described previously (Ikematsu et al, 2000). Briefly,
human MK was produced using Pichia pastoris GS115 by
transfection with a human MK expression vector, which was
constructed into pHIL-D4 (Invitrogen, Carlsbad, California, USA).
This yeast-produced human MK was used to immunise rabbits and
chickens to raise antibodies. The rabbit anti-human MK antibody
(50ml of 5.5mgml
 1 in 50mM Tris HCl (pH 8.2), 0.15 M NaCl, 0.1%
NaN3) was coated onto the wells of microtitre plates (Polysorp
plates, Nunc, Rochester, New York, USA) for 20h at room
temperature. After washing with 0.05% Tween 20 in PBS, the wells
were blocked with 300ml of 0.1% casein, 0.01% Microcide I
(aMReSCO) in PBS for 20h at 371C. Plasma samples (10ml each)
were mixed with 100mlo f5 0m M Tris HCl (pH 8.4), 0.5 M KCl, 0.1%
casein, 0.5% BSA, 0.01% Microcide I, and 0.1mgml
 1 peroxidase-
labelled chicken anti-human MK antibody. Aliquots of 50ml of this
mixture were added to wells prepared as described above, and
further subjected to chromogenic detection at OD450 using
tetramethylbenzidine as the substrate. This EIA system shows
linearity from 0 to 4ngml
 1 of MK, and there is no crossreaction
with PTN (Ikematsu et al, 2000).
Plasma samples
Plasma samples were obtained from blood collected from out-
come patients without malignant tumours (n¼17) and neuro-
blastoma patients (n¼220). The information is summarised in
Table 1.
Statistics
For statistical analysis as to stages, the Kruskal–Wallis test was
used to evaluate the statistical differences between groups. The
Mann–Whitney U-test with Bonferroni’s correction was used to
further evaluate the difference between the two groups. For
analysis as to other prognostic factors, the Mann–Whitney U-test
was used. Po0.05 was taken to be statistically significant.
RESULTS
The plasma MK level increases with advancing stages
Plasma samples were collected from children without malignant
tumours and neuroblastoma patients. The information on
individuals and neuroblastomas is summarised in Table 1. Plasma
from individuals without malignant tumours showed low levels of
MK (116–483pgml
 1; median, 205) (Figure 1). These values are
consistent with the data for sera from healthy adults (median,
154pgml
 1; cutoff value, 500pgml
 1) (Ikematsu et al, 2000). The
EIA employed in the present study showed no difference between
serum and plasma (data not shown). These results indicate that the
plasma level of MK does not change with age, and that the cutoff
value can be set as 500pgml
 1 for children.
The plasma MK level increased with advancing neuroblastoma
stages. The median values were 445, 589, 864, 1445, and
2439pgml
 1 for stages 1, 2, 3, 4, and 4S, respectively (Figure 1).
The percentages of patients showing MK levels of more than the
cutoff value were 38.4, 59.0, 70.0, 83.9, and 91.7% for stages 1, 2, 3,
4, and 4S, respectively (Figure 1). The statistical significance is
summarised in Table 2. Although stage 4S is included in the
favourable neuroblastomas along with stages 1 and 2, the MK level
was the highest at stage 4S among the stages. This may be
interpreted as indicating that one of the parameters influencing the
plasma MK level is the tumour volume.
An elevated plasma MK level is correlated with poor
prognostic factors of neuroblastomas
The neuroblastoma is one of the best studied tumours. Several
factors have been determined to be significantly linked to the
prognosis. Cases with amplified MYCN show a poor prognosis
(Brodeur et al, 1984). Low-level expression of the NGF receptor
Trk A is linked to a poor prognosis (Nakagawara et al, 1993).
Sporadic neuroblastomas show a worse outcome as compared with
neuroblastomas detected by mass screening that is currently being
carried out in Japan (Sawada, 1986). Neuroblastomas with diploidy
or tetraploidy show a worse prognosis than those with hyper-
diploidy or pentaploidy (Look et al, 1984). In addition, the
outcome in patients of older than 1 year is worse compared with in
patients of younger than 1 year (Fortner et al, 1968). All these
prognostic factors were significantly correlated with a plasma MK
level (Figure 2 and Table 3). A higher level of MK was correlated
with MYCN amplification (Po0.0001), low expression of TrkA
(P¼0.0005), sporadic neuroblastomas (Po0.0001), diploidy/tetra-
ploidy (P¼0.0007), and older age (P¼0.0299).
DISCUSSION
This study demonstrated that the plasma MK level is significantly
correlated with prognostic factors of human neuroblastomas. The
only exception was that the plasma MK level was the highest at
stage 4S among the stages, although stage 4S belongs to the
favourable group of neuroblastomas. Stage 4S is a special type of
stage 4. Tumours at stage 4S show spontaneous regression (Evans
et al, 1976). Before spontaneous regression, stage 4S exhibits large
tumours and metastasis to the liver, bone marrow, and skin. We
Table 1 Blood samples
n
No malignant tumours 17
o1 year 11
41 year 6
Neuroblastomas 220
Stage 1 73
Stage 2 39
Stage 3 40
Stage 4 56
Stage 4S 12
MYCN amplification   176
MYCN amplification + 21
High TrkA expression 157
Low TrkA expression 53
Mass screening 122
Sporadic 82
Hyperdiploidy/pentaploidy 91
Diploidy/tetraploidy 119
o1 year 154
41 year 52
Sum from each group number does not necessarily match the total number, because
some information is missing for some individuals.
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ypreviously reported that MK mRNA expression in tumour
specimens is very high at all human neuroblastoma stages,
including stage 4S, as compared with that in benign tumours, that
is, ganglioneuromas (Nakagawara et al, 1995). The present data for
plasma MK are, therefore, consistent with our previous data for
mRNA expression in tumours. Taken together, the results for stage
4S suggest that the tumour volume is one of the factors that
influence the plasma MK level. However, the tumour volume may
not be the only factor that controls the plasma MK level, because
we detected many cases that showed a high MK level even at stage
1 (Figure 1). In favourable neuroblastomas, for example, no MYCN
amplification was discovered by mass screening, and we often
observed high MK plasma levels. It should be noted that, even in
favourable neuroblastomas, many cases exhibit poor clinical
courses. We can expect that such cases can be evaluated and
managed by means of monitoring the plasma level of MK. The
importance of the present study is that it provided a chance to
follow up prognosis of the patients with several parameters,
including the plasma MK level. This perspective study is currently
being carried out by our group, which will reveal the biological and
clinical significance of an elevated plasma level of MK.
The present results also indicated that MK could be a candidate
molecular target for therapy for neuroblastomas, because an
elevated plasma MK level is linked with a poor prognosis. Cancer-
related activities of MK have been reported by many laboratories.
These activities include transforming, migrating, fibrinolytic,
mitogenic, antiapoptotic, and angiogenic ones (Kojima et al,
1995; Choudhuri et al, 1997; Kadomatsu et al, 1997; Qi et al, 2000,
2001). Furthermore, we recently succeeded in suppressing tumour
growth by using antisense MK oligodeoxyribonucleotide (Takei
et al, 2001, 2002). Thus, ablation of MK production or disruption
of its signalling pathway could be a strong means of curing
neuroblastomas. Regarding the signalling pathway of MK,
receptor-type protein tyrosine phosphatase z, anaplastic leukaemia
Stage 4S
(91.7%; n=12
Stage 4
(83.9%; n=56)
Stage 3
(70.0%; n=40)
Stage 2
(59.0%; n=39)
Stage 1
(38.4%; n=73)
Normal
(0.0%; n=17)
10 102 103 104 105 106
Midkine (pg ml–1)
Figure 1 The plasma MK level becomes elevated with advancing neuroblastoma stages. The plasma MK level in children without malignant tumours was
205pgml
 1 (median, n¼17). Those at stages 1, 2, 3, 4, and 4S were 445 (n¼73), 589 (n¼39), 864 (n¼40), 1445 (n¼50), and 2439 (n¼12),
respectively. The percentage of cases showing more than the cutoff value (500pgml
 1) is shown in parentheses beneath each stage. The plasma MK level is
significantly elevated at all neuroblastoma stages compared with the normal level. Statistical analysis is summarised in Table 2.
Table 2 Statistical analysis as to stages
Stage Normal Stage 1 Stage 2 Stage 3 Stage 4
1 o0.001
2 o0.001 0.5o
3 o0.001 0.039 0.5o
4 o0.001 o0.001 o0.001 0.5o
4S 0.003 0.001 0.067 0.5o 0.5o
The difference in serum MK level between the six groups was statistically significant
(Po0.0001, by the Kruskal–Wallis test). P-values in this table for differences between
the two groups were derived from the Mann–Whitney U-test with Bonferroni’s
correction.
10 102 103 104 105 106
Midkine (pg ml–1)
Diploidy/
tetraploidy
(74.7%; n=119)
Hyperdiploidy/
pentaploidy
(47.9%; n=91)
Sporadic
(72.0%; n=82)
Mass screening
(45.9%; n=122)
TrkA−
(77.4%; n=53)
TrkA+
(52.2%; n=157)
MYCN+
(95.2%; n=21)
MYCN−
(55.1%; n=176)
Figure 2 Correlation of the plasma MK level with several prognostic
factors of neuroblastomas. Single asterisk, P¼0.0005 or less; double
asterisk, P¼0.0007. The percentage of cases showing more than the cutoff
value (500pgml
 1) is shown in parentheses. Statistical analysis is
summarised in Table 3.
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identified as MK receptors (Maeda et al, 1999; Muramatsu et al,
2000; Stoica et al, 2002). Although it has not been elucidated yet
whether or not these receptors form complexes for MK signalling,
each protein serves as a receptor transducing intracellular signals
for midkine. Further investigation of the MK action mechanism
should provide insights as to a therapeutic strategy against
aggressive neuroblastomas.
A recent report that 13-cis-retinoic acid could be a curative
reagent for neuroblastomas (Matthay et al, 1999) prompted us to
examine the effect of this reagent on MK production, because MK
overproduction should make the prognosis worse if 13-cis-retinoic
acid induced MK production. All-trans-retinoic acid as well as
13-cis-retinoic acid induced the intracellular production of MK,
but did not enhance the secretion of MK, probably because of
premature binding, as described below (manuscript in prepara-
tion). The endocytosis of MK is completely dependent on LRP, and
initiates nuclear targeting by MK, which is partly needed for the
antiapoptotic activity of MK (Shibata et al, 2002). In addition, LRP
functions as a biosynthesis regulator for MK. Overexpression of
MK leads to premature binding and aggregation of MK and LRP in
the endoplasmic reticulum during the biosynthesis of both
proteins, thus preventing MK overproduction that might cause
overgrowth or transformation of cells (manuscript in preparation).
Taken together, the present results suggest that MK production
during tumour development needs enhancing mechanisms at least
at two steps: mRNA expression and protein secretion.
One of the characteristics of MK expression is that it is
frequently and highly expressed in malignant tumours regardless
of the tissue type. This phenomenon is reminiscent of mutations in
the p53 gene. We previously reported that an elevated serum MK
level was detected in more than 80% frequency of human adult
carcinomas (Ikematsu et al, 2000). Thus, monitoring of the level of
the blood MK is applicable not only to neuroblastomas but also to
adult carcinomas. Further assessment of the blood MK level with
regard to tumour stages and prognosis of adult malignancy will
provide indications for the use of blood MK as a tumour marker
for each disease.
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